201 related articles for article (PubMed ID: 35105671)
1. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Gao X; Wang Y; Ribeiro CF; Manokaran C; Chang H; Von T; Rodrigues S; Cizmecioglu O; Jia S; Korpal M; Korn JM; Wang Z; Schmit F; Jiang L; Pagliarini R; Yang Y; Sethi I; Signoretti S; Yuan GC; Loda M; Zhao JJ; Roberts TM
Mol Cancer Res; 2022 May; 20(5):673-685. PubMed ID: 35105671
[TBL] [Abstract][Full Text] [Related]
2. Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion.
Wang H; Zhou Y; Chu C; Xiao J; Zheng S; Korpal M; Korn JM; Penaloza T; Drake RR; Gan W; Gao X
Mol Cancer Res; 2023 Dec; 21(12):1317-1328. PubMed ID: 37606694
[TBL] [Abstract][Full Text] [Related]
3. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
He C; Duan S; Dong L; Wang Y; Hu Q; Liu C; Forrest ML; Holzbeierlein JM; Han S; Li B
Prostate; 2017 Aug; 77(11):1187-1198. PubMed ID: 28631436
[TBL] [Abstract][Full Text] [Related]
5. Identification of
Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
[TBL] [Abstract][Full Text] [Related]
6. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
7. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM
Cancer Discov; 2013 Jan; 3(1):44-51. PubMed ID: 23258246
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
[TBL] [Abstract][Full Text] [Related]
10. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
12. Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Nikhil K; Kamra M; Raza A; Shah K
Cancer Lett; 2021 Feb; 498():1-18. PubMed ID: 32931887
[TBL] [Abstract][Full Text] [Related]
13. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
[TBL] [Abstract][Full Text] [Related]
16. Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer.
Shangguan X; Ma Z; Yu M; Ding J; Xue W; Qi J
Cancer Res; 2022 Sep; 82(17):3032-3044. PubMed ID: 35767703
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Nollet EA; Cardo-Vila M; Ganguly SS; Tran JD; Schulz VV; Cress A; Corey E; Miranti CK
Oncogene; 2020 Jul; 39(31):5390-5404. PubMed ID: 32565538
[TBL] [Abstract][Full Text] [Related]
18. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
19. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
20. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Xie S; Ni J; McFaline-Figueroa JR; Wang Y; Bronson RT; Ligon KL; Wen PY; Roberts TM; Zhao JJ
Cell Rep; 2020 Sep; 32(13):108196. PubMed ID: 32997991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
